{
    "nctId": "NCT01891227",
    "briefTitle": "Capecitabine + Bendamustine in Women With Pretreated Locally Advanced or Metastatic Her2-negative Breast Cancer",
    "officialTitle": "Capecitabine in Combination With Bendamustine in Women With Pretreated Locally Advanced or Metastatic Her2-negative Breast Cancer, a Phase II Trial",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 40,
    "primaryOutcomeMeasure": "Efficacy of capecitabine + bendamustine combination regimen",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Signed informed consent\n* Female patients, age \u2265 18 years (women of childbearing potential must have a negative pregnancy test at screening and must use effective contraception)\n* Advanced or metastatic Her2-negative breast cancer, histologically confirmed\n* At least one measurable lesion according to RECIST criteria (Version 1.1)\n* Documented disease progression\n* Patients with progression after anthracycline and/or taxane treatment(palliative or adjuvant)\n* Life expectancy of at least 12 weeks\n* Performance status 0-2\n* Hematologic:\n\n  * ANC (absolute neutrophil count) \u2265 1.5 x 109/L\n  * Hemoglobin \u2265 9 g/dL\n  * Platelets \u2265 100 x 109/L\n* Liver Function:\n\n  * Albumin \u2265 2.5 g/dL\n  * Serum bilirubin \u2264 2 mg/dL\n  * AST (Aspartate aminotransferase) and ALT (Alanine aminotransferase) \u2264 3 x ULN (Upper limit of Normal) without liver metastases\n\n    * 5 x ULN if documented liver metastases\n* Renal Function:\n* Serum Creatinine \u2264 1.5 mg/dL OR Calculated Creatinine Clearance \u2265 40 mL/min\n\nExclusion Criteria:\n\n* Pregnant or lactating women\n* Serious medical or psychiatric disorders that would interfere with the patient's safety or informed consent\n* Radiation of the target lesion within the last 4 weeks\n* Active bacterial, viral or fungal infection\n* Patients with clinically apparent brain metastases\n* Known Positivity for HIV\n* Positivity for Hepatitis B or C\n* History of other malignancy; patients who have been disease-free for 5 years or patients with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible.\n* Concurrent cancer therapy (chemotherapy, immunotherapy, antihormonal or biologic therapy) or concurrent treatment with an investigational drug\n* Antihormonal therapy must have been discontinued prior to start of treatment (if possible at least 3 weeks before)\n* Known hypersensitivity to the study drugs capecitabine and bendamustine or their excipients\n* Pretreatment with capecitabine (pretreatment with infusional 5-FU (Fluorouracil) in the adjuvant or neoadjuvant setting is allowed) or bendamustine\n* Treatment with sorivudine or derivates e.g. brivudin (Mevir\u00a9) within the last 4 weeks before and during study treatment with capecitabine",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}